Warning Patients’ Relatives of Genetic Risks: Policy Approaches by Lacroix, Mireille et al.
Warning Patients’ Relatives of Genetic Risks: 
Policy Approaches 
GenEditorial 
editorial on the ethical, legal  
and social issues of human genetics 
(2005) 3:3 GenEdit, 1-8 
 
 
 
Mireille Lacroix1, Béatrice Godard2, and Bartha Maria Knoppers1
 
As an increasing number of genetic tests for specific early- and late-onset disorders move 
from research to the clinical setting, health care professionals are faced with new 
challenges or, alternatively, with novel twists on age-old ethical dilemmas. A finding that 
an individual carries a deleterious mutation can indicate that his or her relatives are at an 
increased risk of being affected by the same genetic disorder.1  
 
 
Though most patients share such risk 
information with their family once aware of 
its broader implications, some individuals 
refuse to do so.2 This places the health care 
professional in a quandary, particularly when 
the disorder in question is serious and 
preventable or treatable. On one hand, the 
health care professional owes the patient a 
duty to keep the information secret, and on 
the other, he or she has a duty to act for the 
benefit of others, including the family 
members who have a significant interest in 
knowing that they may be at risk. The 
potential benefit of this knowledge for the 
patient’s relatives therefore calls into 
question the duty of confidentiality of the 
health care professional.  
 
 
 
 
This edition of GenEdit will briefly examine 
the legal and ethical duties of health care 
professionals, and the policy approaches 
that have been adopted at the international, 
regional and national levels to address the 
dilemma created by a patient’s refusal to 
share relevant genetic risk information with 
those who are at risk. 
 
A. The Health Care Professional’s Legal 
and Ethical Duty of Confidentiality  
 
The duty of confidentiality has been a 
fundamental element of medical ethics since 
antiquity. Based on values of autonomy, 
respect for personal integrity and trust, its 
importance continues to be emphasised in 
the codes of ethics of various health 
professions.3   
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The 2004 CMA Code of Ethics for example 
states that physicians must “[p]rotect the 
personal health information of [their] 
patients” and may disclose such information 
only with their patients’ consent or as 
provided for by law.4   
 
The legal duty of confidentiality has its 
source in a number of privacy protection 
statutes, health laws, regulations governing 
health care institutions and professionals, as 
well as common law rules and civil law 
principles. Briefly stated, the legal duty 
entails that health care professionals must 
keep information they receive in the context 
of a therapeutic relationship in confidence, 
unless the patient consents to its disclosure. 
Confidentiality is not, however, absolute. 
Exceptions to the general rule authorise 
health care professionals to disclose 
confidential information to third parties in 
limited circumstances. These vary across 
jurisdictions, but generally include situations 
in which there are paramount reasons for 
breaching confidentiality, such as when 
disclosure can limit or prevent a serious and 
imminent harm to the health or safety of an 
individual or a group of individuals. In North 
America, exceptions have been recognised 
in cases of suspected child abuse, risk due 
to an infectious disease, and the utterance 
of threats of physical harm towards third 
parties.  
 
While a small number of jurisdictions have 
enacted laws that specifically address 
genetic information and its disclosure to 
family members, in most countries, the 
processing of this type of personal 
information is governed by general privacy 
or personal data protection statutes. These 
statutes provide valuable protection for 
individual interests in the confidentiality of all 
types of sensitive data, including, by 
definition, genetic information. However, 
they fail to take into account its familial 
nature. Family members are considered in 
the same manner as other third parties 
(such as employers, financial institutions, or 
one’s neighbour) and therefore subject to 
the same rules.  
 
 
 
The statutory exceptions that authorise the 
non-consensual disclosure of personal 
information for purposes related to the 
protection of a third party are limited in 
scope and may apply only exceptionally to 
genetic risk information.  
 
In many Canadian provinces for example, 
disclosure is not authorised unless the risk is 
imminent, results from an emergency 
situation, or constitutes a risk of serious 
injury or death. As a result, the disclosure of 
genetic risk information to family members 
may be prohibited even if there is a highly 
probable, serious and preventable risk to 
their health. A number of genetic-specific 
statutes, as well as policies, guidelines and 
recommendations developed by 
professional and other organizations on the 
subject of privacy and genetic information 
attempt to strike a balance between the 
rights of patients and family members. 
 
B. Possible approaches 
 
There are at least five different approaches 
possible when attempting to solve this 
dilemma. A first approach is based on the 
current, atomistic model of health care and 
adopts a rule of strict confidentiality. In order 
to maintain the inherent trust in the health 
care professional-patient relationship, the 
professional cannot disclose information 
about the patient to a third party, including 
the patient’s family members, without his or 
her consent. The moral obligation to disclose 
genetic risks, if any, is that of the patient. 
The professional’s ethical duty is fulfilled 
when he or she informs the patient of the 
relevance of the genetic information for 
family members, and attempts to persuade 
him or her of the importance of sharing it 
with those at risk.5 In addition, the 
professional can provide tools such as 
documentation to assist the patient in 
communicating with relatives.6  
 
This approach, adopted by the European 
Parliament,7 the French National 
Consultative Ethics Committee for Health 
and Life Sciences,8 the American Society of 
Clinical Oncology,9 the Council on Ethical 
and Judicial Affairs of the American Medical 
Association,10 and the Canadian Cystic 
Fibrosis Foundation11 among others, 
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preserves the therapeutic relationship and 
protects the family’s interests, particularly 
where sufficient time is allowed for effective 
counselling.  
 
It however presumes close family ties and 
functional relationships, an assumption that 
does not apply to all families.  
 
A second approach, based on the principle 
of mutuality, characterises genetic risk 
information as familial information.12 Though 
the relevant relationship may be, as in the 
first model, that of the individual patient and 
the health care professional, the shared 
nature of genetic information entails that the 
patient is not entitled to confidence. Under 
this approach, the health care professional 
would have a broad ethical duty to warn the 
patient’s family members of genetic risks if 
the patient refuses to do so himself or 
herself. If this ethical duty becomes a 
standard of practice, it could evolve into a 
positive legal duty, rather than a permissive 
exception to confidentiality. This approach 
would have significant implications for the 
therapeutic relationship, as it would 
fundamentally change the health care 
professional’s role. Brought to its ultimate 
conclusion, it could also lead to the position 
that the patient is the family rather than the 
individual seeking care, which would have 
considerable legal ramifications.  
 
The World Health Organization tends toward 
this approach. It specifically recognises that 
“genetic information may affect an entire 
family,” and recommends that “[t]he 
provision of genetic information to relatives 
about the family so as to learn their own 
genetic risk should be possible, especially 
when a serious burden can be avoided.” 13 
However, it also recognises that the primary 
moral duty of informing family members of 
the existence of a genetic risk does not rest 
with the health care professionals, as it 
recommends to health care professionals 
that they inform their patients that it is their 
(the patients’) responsibility to communicate 
to their blood relatives that they may be at 
risk.   
 
The third approach is based on a 
modification of the implicit contract that 
governs the physician-patient relationship. 
 It involves informing the patient, prior to 
testing, that in the presence of certain 
circumstances the health care professional 
will disclose relevant genetic risk information 
to family members regardless of the 
patient’s intentions. The presumption of 
confidentiality would stand, but would be 
subject to clear exceptions. The patient 
would have the option to accept these 
conditions and undergo testing as planned, 
to search a health care professional whose 
policies meet the patient’s expectations or to 
forego testing entirely. One could argue that 
the therapeutic relationship would not be 
threatened if the expectations of the 
professional and the patient are clearly 
established from the outset.14 Though the 
patient’s autonomy seems to be respected 
in this approach, his choice may be 
theoretical only given the limited number of 
professionals available in many regions and 
the often limited knowledge of the 
complexity of genetic risks among health 
care professionals. In practice then, this 
approach may on the contrary be coercive, 
leaving patients with the perception that they 
have no real choice.15     
 
The fourth approach reflects an intermediary 
position: as a general rule, the patient’s right 
to confidentiality must be respected; 
however, the non-consensual disclosure of 
confidential information may be considered 
ethically permissible in exceptional 
circumstances. A number of guidelines, 
policies and recommendations espouse this 
approach.16 The seriousness of the potential 
harm, its preventability, and the necessity of 
disclosure are key elements of the 
justification for disclosure.  
 
For example, the World Medical 
Association’s position is that exceptions to 
medical secrecy are justifiable only if the 
disclosure of information could avert a 
serious harm and if it is limited to relevant 
genetic information. Even in such cases, 
breaching patient confidentiality is a last 
resort, as all efforts must have been made to 
convince the patient to share the information 
himself/herself.17   
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Other policies require additional elements 
such as a high probability of harm, a high 
likelihood that the information will be used to 
avert harm, the absence of any reasonable 
alternatives to non-consensual disclosure 
and a balance of potential harms and 
benefits that favours disclosure.  
 
While most guidelines and policies leave the 
interpretation and application of these 
criteria to health care professionals, some 
jurisdictions require the approval of an ethics 
committee18 or of a competent agency or 
authority.19
 
This intermediary approach would not 
impose a legal obligation on health care 
professionals to warn family members. It 
would simply provide an ethical justification 
for doing so, as well as a defence against a 
possible complaint for breach of 
confidentiality. It has the advantage of 
protecting the therapeutic relationship and 
the patient’s expectation of confidentiality 
while recognising that in exceptional 
circumstances, the needs of family members 
may be given precedence.   
 
The fifth and final approach is also based on 
the acknowledgment of an exception to the 
general rule of confidentiality. As in the 
fourth approach, a health care professional 
could breach the recalcitrant patient’s right 
to confidentiality when in the presence of a 
foreseeable and highly likely risk of serious 
yet preventable harm to identifiable 
individuals. In this case however, the 
disclosure would be made to an 
independent organisation or agency that 
would then transfer the relevant information 
to each family member’s physician if one is 
known, or to a health care professional who 
would contact the family members and 
provide guidance for follow up care. France 
has adopted a variation of this approach 
when it revised its Bioethics Laws in 2004. It 
seems to give the concerned patient the 
legal responsibility of warning family 
members of genetic risks, but implements a 
procedure that involves the physician. When 
a patient is diagnosed with a serious 
anomaly for which a treatment or preventive 
measure exists, the physician must provide 
the patient with a written and verbal 
explanation of the potential harm to which 
non-disclosure of the genetic risk could 
expose family members.  
 
The patient then has two options: he can 
disclose the information himself or avail 
himself of the “procedure for medical 
information of a familial nature.” If he 
chooses the latter option, he gives the 
physician the names, addresses and degree 
of familial relation of each family member. 
The physician sends the relevant 
information to the “Agence de la 
biomédecine” who then informs the family 
members through a second physician of the 
availability of familial medical information 
that could be relevant to their health.20  This 
approach has the advantage of recognising 
both the value of medical confidentiality and 
the significance of genetic risk information 
for family members, while not placing health 
care professionals in the difficult position of 
contacting individuals with whom they have 
no professional relationship to inform them 
of a health risk. To that extent, it adopts a 
strategy that has proven effective for 
decades in public health: the reporting of 
risk and subsequent provision of information 
to at-risk individuals by specialist third 
parties. It however carries the disadvantage 
of requiring the creation of elaborate 
administrative processes.  
  
C. Discussion: Balancing Interests in 
the Protection of Confidentiality and 
in the Prevention of Harm 
 
These various policy approaches attempt to 
establish a balance between two morally 
valuable social interests: the protection of 
medical confidentiality and the prevention of 
harm. Though the duty of confidentiality is 
not absolute, it is a cornerstone of the health 
care professional-patient relationship. It is 
essential to creating the climate of trust 
required in a therapeutic relationship,21 it 
respects the moral integrity of patients and 
their right to control information about 
themselves, and it complies with the implicit 
undertakings of health care professionals 
whose professions promote confidentiality 
through their codes of ethics.22 Ultimately, 
confidentiality benefits society because it 
leads to better health and to the prevention 
of disease.23 As such, it cannot be set aside 
lightly. 
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The prevention of harm and suffering 
associated with genetic disorders also 
benefits society and, in some 
circumstances, may justify breaching 
confidentiality. Genetic disorders can have a 
significant impact on the lives of individuals, 
including premature death, chronic pain or 
physical ailment, severe psychological or 
behavioural impairment, as well as social 
ramifications and the financial stress linked 
to ill-health.  
 
They can also affect the lives of those who 
are close to the afflicted individual, 
potentially creating social and familial 
hardships. When such serious harms are 
highly likely and preventable, the disclosure 
of a genetic risk can clearly benefit at-risk 
family members. 
 
However, not all genetic disorders share 
these characteristics.  
 
- not all genetic disorders are equally 
serious. Some disorders may, in their 
mild forms, present symptoms that do 
not create serious impairment or to 
which affected individuals can adapt.24 
The evaluation of the magnitude of harm 
is a complicated matter firstly because 
variable expressivity and penetrance 
entail that it is difficult in many cases to 
predict how a genetic disorder will affect 
an individual’s health. In addition, the 
characterisation of the effects of a 
disorder is highly subjective since 
perception of disease, impairment and 
quality of life varies greatly among 
individuals, families and even 
geneticists.25 The perception and the 
actual impact of a disorder on the lives 
of those who are affected depend on a 
number of factors, including one’s 
economic, social and cultural 
environment. Psychological harm is also 
very difficult to evaluate, particularly in 
the absence of knowledge about an 
individual’s personal circumstances. 
 
- the probability of harm associated with 
genetic disorders is highly variable. At 
one end of the spectrum, the risk of 
transmission of monogenic diseases is 
clear and may be as high as 50%, while 
at the other end, the risk of transmission 
of common complex disorders is difficult 
to predict and is much lower. In the 
latter cases, genetics is but one factor in 
the materialisation of the disorder. 
 
- most genetic disorders are not currently 
preventable or treatable. In some cases, 
the available preventive measures are 
of limited efficacy or carry their own risk 
of harm because they are invasive or 
can entail side effects. These must be 
taken into account in evaluating the 
benefit of disclosure. However, even if a 
disorder is not preventable, disclosing 
the existence of a genetic risk may 
foster the autonomy of at-risk family 
members. 
 
In addition, the non-consensual disclosure of 
genetic risk information can be harmful at 
various levels: 
 
- at an individual and societal level, it 
could have a considerable negative 
impact on trust in geneticists and health 
care professionals in general, which 
would diminish professionals’ ability to 
provide adequate care and to conduct 
prevention activities;26 
 
- disclosing genetic risk information to a 
patient’s family members after the 
patient has expressly refused to do so 
would show utmost disregard for his or 
her autonomy and moral integrity, and 
could lead to mental and emotional 
distress for the patient as well as the 
family members;27 
 
- it could have repercussions on the 
patient’s relationship with his or her 
close relatives, particularly if it brings to 
light sensitive issues;28  
 
- it could infringe on the family member’s 
autonomy if he or she prefers not to 
know of the risk;29 and 
 
- if disclosure became a standard of care, 
it would fundamentally change the 
professional’s role, making the 
therapeutic relationship “subservient to 
a more diffuse public health obligation, 
benefiting an unspecified number of 
nonpatient relatives.”30 
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Given the variability of genetic conditions 
and the numerous factors that can have an 
impact on the ramifications of the disclosure 
of a genetic risk, it is not possible to develop 
precise rules or policies of general 
application. These cases necessarily involve 
a measure of professional judgement. In our 
opinion, health care professionals should not 
be imposed a positive duty to warn.  
 
The primary ethical responsibility to warn 
family members of a genetic risk should rest 
with the patients, since they are in the best 
position to communicate with their relatives. 
However, if a patient refuses to do so, health 
care professionals should have the legal and 
ethical discretion to inform the patient’s 
family members of the genetic risk. This 
option should be available as a last resort 
only. Before a breach of confidentiality is 
contemplated, health care professionals 
should be required to ensure that all other 
options have been explored, namely by 
considering whether the risk information 
could possibly be communicated without 
revealing any personal information, 
informing patients prior to testing of the 
potential significance of results for family 
members, attempting to convince patients of 
the need to share the information with at-risk 
relatives through appropriate counselling 
before and after testing, and offering 
assistance to patients who are 
uncomfortable with communicating the 
information. Taking these steps may 
eliminate in many cases the need to resort 
to breaching confidentiality.  
 
Finally, fostering the acceptance of genetic 
information as normal medical information of 
particular importance for family members 
may lead to a shift in values from individual 
autonomy to principles such as reciprocity, 
mutuality and solidarity. 31 This would 
ensure that in the future, genetic risk may be 
freely shared within families in the ethos of 
mutuality and solidarity. 
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